Tissue Factor Pathway Inhibitor (TFPI): Biochemistry, Genetics, and Implications for Thrombophilia;Tissue Factor Pathway Inhibitor (TFPI): Biochemie, Genetik und Stellenwert für die Thrombosenelgung

LaboratoriumsMedizin

Volumn 25, Issue 7-8, 2001, Pages 269-276

  Brinkmann, T ^a   Schmidt, M ^a   Prohaska, W ^a   Kleesiek, K ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

AMINO ACID SUBSTITUTION; BLOOD CLOTTING; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GERMANY; HETEROZYGOTE; PREVALENCE; REVIEW; RISK FACTOR; THROMBOPHILIA; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0034801752     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labm.2001.25.7-8.269     Document Type: Article

References (77)

1. Broze, GJ, Jr., Warren, LA, Novotny, WF, Higuchi, DA, Girard, J, Miletich, JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-TF complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988;71:335-43.
2. Novotny, W. Tissue factor pathway inhibitor. Semin Thromb Hemost 1994;20:101-8.
3. Rapaport, SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemostasis 1991;66:6-15.
4. Lindahl, AK, Sandset, PM, Abildgaard, U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrin 1992;3:439-49.
5. Broze, GJ, Jr. Tissue factor pathway inhibitor. Thromb Haemostasis 1995;74:90-3.
6. Broze, GJ, Jr. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci USA 1987;84:1886-90.
7. Wam-Cramer, BJ, Rao, LV, MakiSL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that effect ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemostasis 1988;60:453-6.
8. Broze, GJ, Jr., Girard, TJ, Novotny, WR Regulation of coagulation by multivalent Kunitz-type inhibitor. Biochem 1990;29:7539-46.
9. Lindahl, AK, Jacobsen, PB, Sandset, PM, Abildgaard, U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrin 1991;2:713-21.
10. Broze, GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrin 1995;6:7–13.
11. Sala, N, Fontcuberta, J, Rutlant, MLL. New biological concepts on coagulation inhibitors. Intens Care Med 1993;19:3–7.
12. Rao, LMW, Rappaport, SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987;69:645-51.
13. 166are essential for rapid formation of the quartemary complex of tissue factor-Vila with Xa-tissue factor pathway inhibitor. Biochem 1995;34:10867-71.
14. Rapaport, SI, Rao, LVM. The tissue factor pathway: how it has become a “prima ballerina”. Thromb Haemostasis 1995;74:7–17.
15. Wun, TC, Kretzmer, KK, Girard, TJ, Miletich, JP, Broze, GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988;263:6001-4.
16. Van der Logt, CPE, Reitsma, PH, Bertine, RM. Intron-Exon organisation of the human gene coding for the lipoprotein-associated coagulation inhibitor: the factor Xa dependent inhibitor of the extrinsic pathway of coagulation. Biochem 1991;30:1571-7.
17. Broze, GJ Jr., Lange, GW, Duffin, KL, MacPhail, L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrin 1994:5:551-9.
18. Nordfang, O, Bjorn, SE, Valentin, S, Nielsen, LS, Wildgoose, P, Beck, TC, Hedner, U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochem 1991;30: 10371-6.
19. Warshawsky, I, Broze, GJ, Jr., Schwarz, AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci 1994;91:6664-8.
20. Valentin, S, Nordfang, O, Brengengard, C, Wildgoose, P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrin 1993;4:713-20.
21. Narita, N, Bu, G, Olins, GM, Higuchi, DA, Herz, J, Broze, GJ Jr., Schwartz, AL. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 1996;270:24800-4.
22. Osterud, B, Bajaj, MS, Bajaj, SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemostasis 1995;73:873-5.
23. Colburn, P, Buonassisi, V. Identification of an endothelial cell product as an inhibitor of tissue factor activity. Vitro Cellular & Developmental Biology 1984;24:1133-6.
24. Hansen, JB, Huseby, NE, Sandset, PM, Svensson, B, Lyngmo, V, Nordoy, A. Tissue factor pathway inhibitor and lipoproteins. Arterioscl Thromb Vas 1994:14:223-9.
25. Warn-Cramer, BJ, Almus, FE, Rapaport, SI. Studies of the factor Xa-dependent inhibitor of factor VIIa/TF (Extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells. Thromb Haemostasis 1989;61:101-5.
26. Abildgaard, U. Tissue factor pathway inhibitor and heparin. Heparin and related polysaccharides. Plenum Press, New York, 1992, pp. 199–203.
27. Bajaj, MS, Kuppuswamy, MH, Saito, H, Spitzer, SG, Bajaj, SP. Cultured normal human hepatocytes do not synthezise lipoprotein-associated coagulation inhibitor; evidence that endothelium is the principle site of its synthesis. Proc Natl Acad Sci 1990;87:8869-73.
28. McGee, MP, Foster, S, Wang, X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes-a potential mechanism for localized control of blood coagulation. J Exp Med 1994;179:1847-54.
29. Van der Logt, CPE, Dirven, RJ, Reitsma, PH, Bertina, RM. Expression of tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharides and phorbolester. Blood Coagl Fibrin 1994;5:211-20.
30. Novotny, WF, Brown, SG, Miletich, JP, Rader, DJ, Broze, GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood-1991;78:387-93.
31. -Invest 1987;79:1874-8.
32. Brinkmann, T, Kahnert, H, Prohaska, W, Nordfang, O, Kleesiek, K. Synthesis of tissue factor pathway inhibitor in human synovial cells and chondrocytes makes joints the predilected site of bleeding in haemophiliacs. Eur J Clin Chem Clin Biochem 1994;32: 313-7.
33. Novotny, WF, Girard, TJ, Miletich, JP, Broze, GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988;72: 2020-5.
34. Lesnik, P. Vonica, A, Guerin, M, Moreau, M, Chapman, MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscl Thromb Vas 1993;13:1066-75.
35. Ariens, RAS, ALberio, G, Moia, M, Mannucci, PM. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemostasis 1999;81:203-7.
36. Novotny, WF, Brown, SG, Miletich, JP, Rader, DJ, Broze, GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-93.
37. Hansen, JB, Huseby, KR, Huseby, NB, Sandset, PM, Hanssen, TA, Nordoy, A. Effect of cholesterol lowering on intravascular pools of TFPI and ist anticoagulant potential in type IJ hyperlipoproteinemia. Arterioscl Thromb Vas 1995;15:879-85.
38. Lindahl, AK. Tissue factor pathway inhibitor in health and disease. TCM 1995;5:167-71.
39. Kokawa, T, Abumiya, T, Kimura, T, Harada-Shiba, M, Koh, H, Tsushima, M, Yamamoto, A, Kato, H. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperiipidemia. Arterioscl Thromb Vas 1995;15:504-10.
40. Moor, E, rfamsten, A, Karpe, F, Bavenholm, P, Blomback, M, Silveira, A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemostasis 1994;71:707-12.
41. Hamsten, A, Erikson, P, Karpe, F, Silveira, A. Relationship of thrombosis and fibrinolysis to atherosclerosis. Curr Opin Lipidol 1994;5:382-9.
42. Warn-Cramer, BJ, Maki, SL, Rapaport, SI. A sulfated rabbit endothelial cell glycoprotein that inhibits factor VIIa/TF is functionally and immunologically identical to rabbit extrinsic pathway inhibitor (EPI). Thromb Res 1991;61:515-27.
43. Van der Logt, CPE, Kluck, PMC, Wiegant, J, Landegent, JE, Reitsma, PH. Refined regional assigment of the human tissue factor pathway inhibitor (TFPI) gene to chromosome band 2q32 by nonisotopic in situ hybridisation. Hum Genet 1992;89:557-78.
44. Enjyoji, KI, Emi, M, Mukai, T, Imada, M, Leppert, ML, Lalouel, JM, Kato, H. Human tissue factor pathway inhibitor (TFPI) gene: complete genomic structure and localization of the genetic map of chromosome 2q. Genomics 1993;17:423-8.
45. Girard, TJ, Eddy, R, Wesselschmidt, RL, MacPhail, LA, Likert, KM, Byers, MG, Shows, TB & Broze, GJ Jr. Structure of the human lipoprotein-associated coagulation inhibitor gene. J Biol Chem 1988;266:5036-41.
46. Tyson, DR, Kuppuswamy, MN, Broze, GJ, Bajaj, SP. Revised DNA sequence of exon 1 and 5‘ flanking region of the human tissue factor pathway inhibitor gene. Thromb Res 1993;70:269-73.
47. Sandset, PM, Warn-Cramer, BJ, Maki, SL, Rapaport, SI. Immunodepletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991;88:708-12.
48. Sandset, PM, Warn-Cramer, BJ, Maki, SL, Rapaport, SI. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 1991;78 1496–1502.
49. Creasey, AA, Chang, ACK, Feigen, L, Wün, TC, Taylor, FB Jr., Hinshaw, LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-60.
50. Huang, BZ, Higuchi, D, Lasky, N, Broze, GJ Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997;90:944-51.
51. Sandset, PM, Bendz, B. Tissue factor pathway inhibitor: Clinical deficiency states. Thromb Haemostasis 1997;78:467-70.
52. Broze, GJ Jr. Tissue factor pathway inhibitor gene disruption. Blood Coagul Fibrin 1998; 9 Suppl. 1:89–92.
53. Sanson, BJ, Simioni, P, Tormene, D, Moia, M, Friederich, PW, Huisman, MV, Prandoni, P, Bura, A, Rejto, L, Wells, P, Mannucci, PM, Girolami, A, Büller, HR, Prins, MH. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study. Blood 1999;94:3702-6.
54. Kobayashi, M, Wada, H, Wakita, Y, Shimura, M, Nakase, T, Hiyoyama, K, Nagaya, S, Minami, N, Nakano, T, Shiku, H. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemostasis 1995;73:10-4.
55. Lobet, D, Falkon, L, Mateo, J. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia. Thromb Res 1995;80:413-8.
56. Goodwin, CA, Melissari, E, Kakkar, VV, Scully, MF. Plasma levels of tissue factor pathway inhibitor in thrombophilic patients. Thromb Res 1993;72:363-6.
57. Llobet, D, Falkon, L, Mateo, J, Vallvé, C, Martinez, C, Fontcuberta, J, Borrell, M. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia. Thromb Res 1995;80:413-8.
58. Harris, GM, Stendt, CL, Vollenhoven, BJ, Gan, TE, Tipping, PG. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol 1999;60:175-80.
59. Broze, GJ. Tissue factor pathway inhibitor. Thromb Haemostasis 1995;74:90-3.
60. Ariens, RAS. Alberio, G. Moia, M, Mannucci, PM. Low levels of heparin-releasablc tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemostasis 1999;81:203-7.
61. Kleesiek, K. Schmidt, M, Gmting, C, Brinkmann, T, Prohaska, W. A first mutation in the human tissue factor pathway inhibitor gene encoding |P151L1TFPI. Blood 1998;92:3976-80.
62. Kleesiek, K. Schmidt, M, Götting, C. Schwenz, B. Lange, S. Müller-Bcrghaus, G. Brinkmann, T. Prohaska, W. The 536C→T transition in the human tissue factor pathway inhibitor gene is statistically associated with a higher risk of venous thrombosis. Thromb Haemostasis 1999;82:1–5.
63. Girard, TJ, Warren, LA, Novotny, WF, Likert, KM, Brown, SG, Milctich, JP, Broze, GJ. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 1989;338:518-20.
64. Girard, TJ, Eddy, R. WesseIschmidt, RL, MacPhail, LA, Likert, KM, Byers, MG, Shows, TB, Broze, GJ. Structure of the human lipoprotein-associated coagulation inhibitor gene. J Biol Chem 1991;266:5036-41.
65. Wesselschmidt, R, Likert, K, Girard, T. Wun, TC, Broze, GH. Tissue factor pathway inhibitor: The carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992;79:2004-10.
66. Broze, GJ, Warren, LA, Novotny, WF, Higuchi, DA, Girard, JJ, Miletich, JP. The lipoprotein-associated coagulation inhibitor that inhibits the vactor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1984;71: 335.
67. 243of the third Kunitz domain is a heparin-binding site. Biochemstry 1995;34:5725-35.
68. NakaharaY, Miyata T, Hamuro, T, Funatsu, A, Miyagi, M, Tsunasawa, S, Kato, H. Amino acid sequence and carbohydrate structure of a recombinant human tissue factor pathway inhibitor expressed in Chinese ovary cells: One N- and two O-linked carbohydrate chains are located between Kunitz domains 2 and 3 and one N-linked carbohydrate chain is in Kunitz domain 2. Biochemistry 1996;35:6450-9.
69. Paciaronj, K, Rossi, E. Bazzan, M, Ireland, H, De Stefano, V. Prevalence of the C536T Mutation in the Tissue Factor Pathway Inhibitor (TFPI) Gene among Patients with venous Thromboembolic Disease. Thromb Haemostasis 2001;85:938-9.
70. Gonzáles-Conejero, R, Lozano, ML, Corral, J, Martinez, C, Vicente, V. The TFPI 536C→T mutation is not associated with increased risk for venous or arterial thrombosis. Thromb Haemostasis 2000;83:787-8.
71. Evans, GD. Langdown, J, Brown, K, Baglin, TP. The C536T transition in the tissue factor pathway inhibitor gene is not a common cause of venous thromboembolic disease in the UK population. Thromb Haemostasis 2000;83:511.
72. Hessner, MJ, Luhm, RA. The C536T transition in the tissue factor pathway inhibitor (TFPI) gene does not contribute to risk of venous thrombosis among carriers of factor V Leiden. Thromb Haemostasis 2000;84:724-5.
73. Arnaud, E, Moatti, D, Emmerich, J, Aiach, M, de Prost, D. No link between the TFPI V264M mutation and venous thromboembolic disease. Thromb Haemostasis 1999;82:159-60.
74. Moatti, D, Seknadji, P, Galand, C, Poirier, O, Fumeron, F, Desprez, S, Garbarz, M, Dhermy, D, Arveiler, D, Evans, A. Luc, G. Ruidavets, JB, Ollivier, V, Hakim, J, Aumont, MC, de Prost, D. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects. Impact of the V264M substitution on plasma levels of TFPI. Arterioscl Thromb Vas 1999;19:862-9.
75. Miyata, T, Sakata, T, Kumeda, K, Uchida, K, Tsushima, M, Fujimura, H, Kawasaki, T, Kato, H. C399T polymoiphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb Haemostasis 1998;80:345-6.
76. Moatti, D, Haidar, B, Fumeron, F, Gauci, L, Boudvillain, O, Seknadji, P, Ollivier, V, Aumont, MC, de Prost, D. A new T287C poly-morphism in the 5‘ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T287C and C399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haemostasis 2000;84:244-9.
77. Abraham, E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28 Suppl:31-3.